Editor's key points † There is a clinical need for predictive markers of neurological damage in the perioperative period. † The proteins S100B and Tau and the enzyme neurone-specific enolase have been assessed in cardiac and non-cardiac surgery but with conflicting results. † The limited studies of metalloproteinase-9 and ubiquitin C terminal hydroxylase-L1 show some promise. † More studies are required before any of these markers can be recommended.
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In an attempt to address these outcomes, it would be helpful to identify patients at risk, predict their short-and long-term outcomes, monitor them perioperatively, and possibly apply neuroprotective interventions aimed at improving such outcomes. There is no available methodology to test for and measure central nervous system (CNS) reserve in a way that a cardiac stress test would tell about cardiac reserve. Intraoperative monitoring of responsiveness of the awake patient is still considered the gold standard for early detection of neurological insult. 2 3 However, when general anaesthesia is used, that modality monitoring is not available, and the evidence for the utility of EEG is at best controversial. 4 Somato-sensory and motor-evoked potential have been used to detect spinal cord injury during spine surgery. 5 6 However, it has its own limitations. 7 There is considerable interest in neurological biomarkers with the hope that they would meet the current needs.
The ideal neurological biomarker should have similar characteristics to other markers of injury such as cardiac troponins. Thus, the 'brain troponin' should be CNS-specific, easily and cheaply measured in the blood, resistant to cytoplasmic and extracellular proteolytic activity, and not dependent on renal excretion. It should also have a high sensitivity and specificity for predicting short-and long-term outcomes. Consequently, its level should vary with the degree of CNS damage and improve with neuroprotective interventions.
In addition, a reliable neurological biomarker in the context of systemic inflammation, such as in severe sepsis or during cardiopulmonary bypass (CPB), would be important for monitoring the CNS as sepsis-induced encephalopathy prolongs intensive care unit stay and increases mortality. 8 -11 Although there is no strong support for the use of neurological biomarkers in the prognosis of outcome after cardiac arrest, some authorities have recommended their use in the context of mild therapeutic hypothermia.
subjects with genetically mediated predisposition to a specific condition. Effect biomarkers measure early biological effect such as structural or functional changes in affected cells or tissues, or clinical disease. Exposure biomarkers are used to measure chemicals or their metabolites to determine a subject's exposure to them. 13 Thus, the identification of neurological biomarkers that fulfil these characteristics would be useful for the identification of patients at risk and the detection and treatment of those with on-going neurological insults (Fig. 1) .
We have reviewed studies relating to five relevant neurological biomarkers: S100B, neurone-specific enolase (NSE), Tau protein, metalloproteinases (MMPs), and ubiquitin C terminal hydroxylase-L1 (UCH-L1), in the perioperative period of adult cardiac and non-cardiac surgery ( Table 1) .
All relevant studies were identified by computerized searches of PubMed using the following Medical Subject Headings (MeSH) and keywords term: biomarkers, spinal cord injuries, S100 proteins, NSE, 14-3-3 proteins, metalloproteases and ubiquitin, cardiac surgical procedure, aneurysm, endarterectomy, spine, and perioperative period. For all clinical studies, either prospective or retrospective, we report summary data, including outcomes measured, site of biomarker detection, detection tests, and baseline and peak levels of each marker. Animal and human studies published in English language were considered in the review.
S100B protein
The S100B protein is a protein of 21 kDa with a homodimeric structure that belongs to a multigenic family of calcium-mediated proteins (S100 proteins).
14 S100B is encoded on the long arm of the chromosome 21 (21q22.3) and consists of the monomeric subunits B -B in contrast to S100a formed by the monomers A -B and S100a that consists of A1-A1. The S100B dimer is specific to the CNS and the S100a is found in the heart and the aorta. It is essential that an assay for S100B does not cross-react significantly with S100a. 15 S100B has intracellular and extracellular targets, and has autocrine and paracrine effects on glia, neurones, and microglia. This protein is also expressed and secreted into the cerebrospinal fluid (CSF) by astrocytes after CNS injury and is currently labelled as a marker of generalized blood -brain barrier (BBB) dysfunction. 16 However, its exact function still remains unknown. Preclinical and clinical studies suggest that S100B may be involved in neuronal and glial growth, proliferation, and activation, thus facilitating its potential role as a marker in the study of inflammatory and degenerative neurological diseases. 17 -19 The extracellular effect of S100B seems to depend on its concentration; it is neurotropic at nanomolar concentrations and apoptotic at micromolar concentrations. 20 21 The protein has a half-life of 25 min and its elimination is not affected by moderate renal dysfunction. 22 23 Increased serum and CSF levels of S100B are observed after CNS infarction, trauma, or toxic injury. 24 -27 S100B values, however, may differ depending on the assay used for its detection (Fig. 2) . Therefore, researchers have suggested the need of an international standardization for assays of S100B to enable effective assessment of the predictive validity of this biomarker in the routine clinical practice. 28 This is further complicated in the perioperative period as different anaesthetics affect the levels of S100B in the brain. In rats anaesthetized with thiopental, the levels of S100B in the brain were much higher than in those anaesthetized with either halothane or ketamine.
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S100B in cardiac surgery
Animal studies of S100B during cardiac surgery have shown that the immunoreactivity of S100B in the brain of rabbits exposed to CPB and hypothermic circulatory arrest is increased in the astrocytic processes with an immediate connection to the perivascular space and around the perivascular oedema. 30 Researchers suspected that the increase in S100B during CPB is due to brain hypoperfusion. However, several human studies have demonstrated that S100B is elevated in patients undergoing cardiac surgery on CPB regardless whether selective perfusion of the brain is used or not. 31 -34 It is important to note that serum S100B concentrations appear to be influenced by age, gender, chronic hypertension, the use of cardiotomy suction or cell saver, on-vs off-pump surgery, and the assay used for its (Table 2 ). It has also been suggested that 80% of S100B measured during and early after surgery represents a significant contamination from non-neural sources.
22 S100B protein release during and after CPB correlated positively with both age and duration of perfusion. 40 A small cohort study of 22 patients then suggested that preoperative chronic hypertension is associated with higher levels of S100B in cardiac surgery patients. 41 The authors speculated that the poor cerebral blood flow autoregulation secondary to chronic hypertension might predispose BBB dysfunction during CPB and thus initiate the release of S100B. 41 There was a positive correlation between postoperative serum levels of S100B and age in 56 patients who underwent coronary artery bypass graft (CABG) surgery. 42 Genetic susceptibility may influence the serum concentrations of S100B as it has been demonstrated that S100B levels were higher in ApoE 4 carriers than ApoE 2 and 3. 43 ApoE 4 has been associated with other CNS disorders such as Alzheimer's disease (AD) 44 and with deleterious outcome after intracerebral haemorrhage, 45 head trauma, 46 and CPB. 47 It is possible that the time of S100B sampling is more important when the biomarker is used to predict outcomes. S100B levels 24 h after surgery possess a sensitivity and specificity of 90% in identifying patients with cerebral lesions. 48 The relationship between S100B levels and both neurological and neuropsychological outcomes is still under debate. 37 40 49 In a cohort of 20 patients who developed postoperative stroke, there was a correlation between the serum levels of S100B 48 h after operation and the size of the brain infarct. 50 Additionally, those patients who had levels of S100B higher than 0.5 mg dl 21 showed an increased risk of mortality after surgery. 50 Furthermore, S100B showed prognostic value in a pilot study of patients who had CABG surgery and did not show neurological symptoms. Specifically, high serum levels of S100B were associated with longer hospital stay.
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POCD and delirium may occur in up to approximately two-thirds of patients undergoing cardiac surgery.
1 Therefore, there has been a growing interest in finding a biomarker that will permit not only the identification of patients at risk but also predict long-term outcomes. Patients who developed delirium 3 days after surgery had significantly higher and longer serum levels of S100B than non-delirium patients. 52 The patients were followed up for 6 months after surgery, but due to a small sample size, no predictive values could be calculated with respect to the long-term neuropsychological outcome. 52 A cohort of 114 patients who underwent cardiac surgery under CPB showed a correlation between S100B and change in neuropsychological test performance. 40 Interestingly, S100B was measured shortly after surgery and predicted cognitive changes 8 weeks after surgery. 40 In a small cohort study, it was found that serum levels of S100B protein higher than 0.3 mg litre 21 were more commonly observed in patients who had postoperative sleep disturbances after cardiac surgery. 53 In contrast, results from 513 patients who had cardiac surgery demonstrated that preoperative serum S100B is not predictive of postoperative adverse neurological complications. 54 Additionally, two randomized controlled trials could not demonstrate any correlation between S100B levels and neuropsychological outcomes at hospital discharge and 6 weeks after surgery. 37 55 It is important, however, to note that the authors used different laboratory assays to measure serum levels of S100B. Furthermore, no relationship has been shown between serum levels of S100B and BJA Cata et al. neuropsychological dysfunction after CABG. 42 49 56 -58 The latter tried to identify a correlation between several clinical and laboratory measurements and postoperative cognitive defects 3 months after surgery. After a multivariable analysis, only age was associated with POCD. 58 Postoperative memory decline has also been associated with cardiac surgery and CPB. The association between S100B and memory was significant in 415 low-risk coronary artery bypass patients under CPB where an elevated S100B 7 h post-CPB, but not intraoperatively, was an effective predictor of memory decline.
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S100B in non-cardiac surgery
Serum concentrations of S100B have also been investigated in the perioperative period for non-cardiac surgery 60 61 ( Table 2 ). The preclinical evidence suggests that S100B increases during and after non-cardiac surgery. In rabbits with bilateral femur fracture and no evidence of neurological injury, S100B increased within minutes after the bone trauma, suggesting that early perioperative elevations of serum S100B may come from non-neural sources. 62 In patients with chronic cervical myelopathy who underwent uncomplicated spinal surgery, S100B apparently did not predict functional outcome. Conversely, in those with a complicated postoperative course, S100B had prognostic significance. 63 The same group of researchers investigated the predictive value of S100B in patients with intradural spinal lesions and concluded that the postoperative serum S100B did not correlate with functional outcome. 64 Cerebrospinal concentrations of S100B were measured to identify patients at risk of neurological complications in the perioperative period of thoracoabdominal aortic aneurysm (TAAA) surgery. 61 Patients who developed neurological complications had significantly higher levels of S100B. Unfortunately, the concentrations of this biomarker began to increase after the onset of clinical symptoms, which limits its utility as an early marker. 61 In a small cohort study of 28 patients who underwent TAAA repair, some with hypothermic circulatory arrest, the CSF levels of S100B increased in the early postoperative period in those with and without neurological symptoms. 65 However, there were significant differences in those who had neurological dysfunction. In a small study in patients undergoing major vascular surgery, the serum levels of S100B increased during the perioperative period, but the cerebrospinal levels remained low in some patients. The authors argued that surgical trauma itself may be responsible for serum S100B increments in the absence of central nervous injury. 66 A similar study showed that at 5 and 24 h after operation, S100B was significantly higher in patients who underwent hypothermic circulatory arrest than those who did not undergo circulatory arrest. 67 Furthermore, there was a positive correlation between duration of the circulatory arrest and the postoperative levels of the biomarker. 67 Several studies have investigated the predictive value of S100B in the context of carotid endarterectomy (CEA), but the results remain inconclusive. Subtle cerebral injuries after CEA appeared to be associated with significant increases in serum S100B. 68 It has been suggested that intraoperative elevations of S100B during CEA are the result of BBB dysfunction due to transient episodes of cerebral hypoperfusion 69 and to carotid clamping. 70 In two cohort studies of 43 and 20 patients, intraoperative serum concentrations of S100B were elevated during CEA. 70 71 They failed nevertheless to predict cognitive outcome. In a third study in which 27 out of 28 patients underwent CEA under local anaesthesia, it was found that S100B increased intraoperatively and after operation and did not correlate with neurocognitive outcomes. 72 Interestingly, in a study of patients having CEA under local anaesthesia, S100B did not significantly increase. 73 However, no significant differences in S100B levels were found between patients who underwent CEA under either general or local anaesthesia. 74 Carotid artery stenting (CAS) is associated with higher levels of S100B than CEA possibly due to a greater microembolization during CAS than during CEA in which a transient hemispheric period of hypoperfusion is commonly seen.
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S100B has been also investigated in the context of noncardiac non-vascular surgery. After operation, levels of serum S100B were increased in a small cohort of 13 patients (ASA I or II), who underwent extensive oral and maxillofacial surgery for reconstruction of the maxillofacial region. The authors of the study suggested a possible association between low postoperative levels of thyroid hormones and increased levels of S100B. 60 Neurone-specific enolase NSE is a dimeric enzyme that catalyses the conversion of 2-phospho-D-glycerate to phosphoenolpyruvate in the glycolytic pathway and is found in neurones and neuroendocrine cells. The subunits a and g present in NSE are specific for neurones. 75 The molecular weight of NSE is 78 kDa and its half-life is 24 h. 76 Animal studies have demonstrated that NSE is increased after brain cortical injury. 79 80 NSE was effective in predicting neurological outcome and survival after cardiac arrest. 81 82 NSE has also shown to be increased after repetitive, severe head trauma and also in patients with temporal lobe epilepsy. 83 -85 In patients with ischaemic stroke, the release of NSE has been associated with neurological outcomes and infarct volume. 86 
NSE in cardiac surgery
Serum and CSF concentrations of NSE increase during cardiac surgery with CPB and return to baseline values by 24 h after operation. 52 87 The use of cardiotomy suction has been associated with higher levels of NSE after CPB, 88 possibly due to contamination from non-neural sources. It is known
that NSE is found within red cells and platelets; therefore, haemolysis during CPB and the use of cardiotomy suction may result in the release of NSE. 89 Lower temperatures may aggravate that effect, since NSE concentrations are more likely to increase during cardiac surgery with mild or deep hypothermic CPB rather than with normothermic CPB. Off-pump cardiac surgery is often associated with significantly lower concentrations of NSE. 90 91 The origin of NSE has been questioned; however, an early study demonstrated that CSF concentrations of NSE increased during CPB. 92 93 Additionally, in patients undergoing cardiac surgery, arterial -cerebral venous concentration gradients of NSE were not detectable during and after CPB. Only in a specific subgroup of patients, who had hypothermic CPB, arterio-cerebral venous differences were observed. 94 Conflicting results have been found for NSE as a predictor of neurological outcomes after cardiac surgery (Table 3) . A significant association between postoperative neurocognitive dysfunction and serum levels of NSE has been demonstrated. 35 However, in patients who had aortic valve replacement, there was no association between NSE, diffusion-weighted imaging lesions in magnetic resonance scan, and outcome. 33 Similarly, early neuropsychological bedside testing, in contrast to NSE, predicted long-term POCD after CABG. 95 During aortic arch repair, NSE increases even when selective perfusion of the brain is attempted. NSE peaked during anterograde selective cerebral perfusion with no significant difference between the two cerebral hemispheres at any time of the surgery. 34 A small cohort of patients who had the ApoE 4 allele showed significantly higher postoperative serum levels of NSE than those with ApoE 2 and 3. 42 Carriers of the ApoE 4 allele had an increased likelihood of developing AD. 96 Therefore, it may be possible that a genetic susceptibility is responsible for the increased levels of biomarkers and POCD after cardiac surgery. In contrast to cardiac surgery, McDonagh and colleagues 97 showed that NSE levels were not associated with the APOE4 genotype or cognition at 6 weeks or 1 yr after non-cardiac surgery.
NSE in non-cardiac surgery
An investigation of the predictive value of NSE from CSF and serum in patients undergoing aortic aneurysm repair concluded that neither NSE nor S100B could replace or add information to the transcranial motor-evoked potentials monitoring during surgery. 66 In a small cohort of patients who had descending thoracic or thoracoabdominal aorta repair, NSE concentrations in the CSF increased in patients with and without neurological symptoms 65 ( Table 3 ). The increase in NSE after internal cardiac defibrillator implantation was associated with impaired attention and memory after operation. 98 The increase in NSE was associated with the number of shocks and the cumulative time in circulatory arrest. 99 In contrast, NSE was not significantly higher in a small cohort of elderly patients who developed POCD after minor surgery. 100 In patients undergoing orthotopic liver transplantation, post-reperfusion concentrations of NSE correlated with decreased regional cerebral oxygen saturation levels. However, the authors of this study did not assess neurological outcomes in these patients. 101 NSE has been also the primary focus of research in patients undergoing CEA. Preoperative values of NSE are increased in some patients with stenotic lesions of the cerebral arteries and values normalize after revascularization. 69 NSE also increases during and after CEA. However, the concentrations appear to differ with the anaesthetic technique used. 74 In two studies, NSE failed to predict cognitive dysfunction or postoperative neurological deficit in patients undergoing CEA or CAS. 69 71 NSE was also used to assess neurological damage in a randomized controlled trial that compared CEA and CAS which found that NSE was significantly higher in the CAS group than in those who underwent CEA. 102 Other authors have shown the opposite. 69 
Tau protein
Tau is a microtubule-associated protein that stabilizes the axonal microtubules and is found in the brain and spinal cord. Tau protein is encoded by the MAPT gene found on chromosome 17q21.3. It has multiple isoforms and the low molecular weight isoforms range from 45 to 68 kDa 103 ( Table 1) . Phosphorylation of Tau occurs in association with neural death and is observed in neurodegenerative disorders such as AD. As such, phosphorylated Tau is increased in the CSF of AD patients and appears to be a sensitive and specific marker of disease progression. 104 Common perioperative derangements such as hypothermia induce a robust hyperphosphorylation of Tau, 105 as do episodes of transient cerebral ischaemia. 106 Therefore, it is possible that Tau protein phosphorylation may be useful as a marker of postoperative neurological outcome.
Tau in cardiac surgery
Tau protein increases in the perioperative period of cardiac surgery, but concentrations may not be affected by cardiotomy suction and cell saver use. 35 107 This is supported by findings in animals in which the concentrations of Tau in the CSF progressively increased during the hypothermic cardiac arrest-CPB and post-CPB periods. 108 In humans, Tau protein levels peaked 6 h after surgery and returned to baseline by the fourth postoperative day. Importantly, serum levels of Tau were higher in patients with postoperative cognitive disorders. 35 
Tau in non-cardiac surgery
Tau has also been investigated in patients undergoing aortic surgery. Increases in CSF Tau protein in patients undergoing thoracic or thoracoabdominal aortic surgery were higher in those with brain infarction compared with neurologically intact patients. 109 Statistically significant differences were also observed between the patients with transient neurological deficit and those without it. 109 Neurological biomarkers in the perioperative period (Table 1) . Importantly, the expression of MMP-9 around leaky blood vessels is increased. 115 Concentrations of MMP-9 peak early in patients with stroke. 116 Also, MMP-9 is strongly correlated with neuronal death in areas of secondary injury of stroke patients.
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MMP-9 has been studied in the perioperative period. Surgical stress increases its release and enzymatic activity 118 119 and more importantly the systemic levels of MMP-9 appear not to be affected by baseline conditions such as diabetes, smoking status, or hypertension. 120 The concentration of MMP-9 peaks during CEA and correlates with the duration of carotid occlusion. 121 A prospective cohort study identified that patients with cognitive dysfunction after carotid surgery had higher pre-and postoperative plasma levels of MMP-9 than those without cognitive symptoms. 122 Postoperative increments of MMP-9 can represent systemic inflammatory response, local release of the protein due to atherosclerotic plaque manipulation, microembolization, or transient ischaemia with resulting BBB damage. 123 However, the finding of higher preoperative concentrations in patients who developed POCD may represent also a higher 'baseline' inflammatory state or silent areas of ischaemia associated with subclinical BBB dysfunction. This is supported by a study which found that clinical asymptomatic patients with higher preoperative MMP-9 had more neuroimaging cerebral lesions than those without.
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Ubiquitin C terminal hydroxylase-L1
UCH-L1 is a highly specific neuronal protein that is concentrated in the perikarya in grey matter. 124 Its approximate molecular weight is 24 kDa. 125 Its enzymic function is related to the removal of misfolded or oxidized proteins in the CNS. 126 In contrast to NSE and S100B, which are present in non-neural sources, only small amounts of UCH-L1 arise from other tissues such as the testis, which makes it a specific biomarker of CNS insults 127 (Table 1) .
A recent animal study showed that UCH-L1 is released in the CSF after traumatic brain injury. It is also raised after experimental stroke. Hence, it appears that UCH-L1 is a potential biomarker for acute brain injury. 128 Human studies have linked UCH-L1 to degenerative CNS disease such as Parkinson's disease and AD. 129 A mutation in the gene that encode for UCH-L1 has been found in siblings with Parkinson's disease. 130 UCH-L1 has also been measured in the CSF of patients with subarachnoid haemorrhage (SAH). Concentrations were raised through the second week after SAH and beyond which correlated with the peak of S100B. 131 To date, there are no studies of the predictive value of UCH-L1 in the perioperative period or of the effect of anaesthetics on UCH-L1 biology and kinetics.
In conclusion, five different neurological biomarkers have been studied in the perioperative period. Unfortunately, the studies of S100B, NSE, and Tau protein appear to have conflicting results. There are several possible reasons for the conflicting results with S100B, NSE, and Tau. First, although most studies have used similar surgical procedures such as cardiac surgery, individual differences based on genetic polymorphism may explain some of the variability. Secondly, contamination from non-neural sources, particularly for S100B, may make interpretation of results difficult. Thirdly, different assays may have different sensitivities to detect levels of S100B, NSE, and Tau protein. Thus, the results reported by different authors may not be comparable. Few or no studies have been done in humans to identify the role of MMP-9 and UCH-L1 in the perioperative setting.
At this stage, it is difficult to recommend the use of these markers in the diagnosis or prediction of postoperative neurological outcomes. More research is warranted to validate the use of these markers.
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